

Inappropriate Management of Asymptomatic Patients With Positive Urine Cultures: A Systematic Review and Meta-analysis

Myrto Eleni Flokas,^{1,a} Nikolaos Andreatos,^{1,a} Michail Alevizakos,¹ Alireza Kalbasi,² Pelin Onur,¹ and Eleftherios Mylonakis¹

¹Infectious Diseases Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island; and ²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Background. Mismanagement of asymptomatic patients with positive urine cultures (referred to as asymptomatic bacteriuria [ASB] in the literature) promotes antimicrobial resistance and results in unnecessary antimicrobial-related adverse events and increased health care costs.

Methods. We conducted a systematic review and meta-analysis of studies that reported on the rate of inappropriate ASB treatment published from 2004 to August 2016. The appropriateness of antimicrobial administration was based on guidelines published by the Infectious Diseases Society of America.

Results. A total of 2142 nonduplicate articles were identified, and among them 30 fulfilled our inclusion criteria. The pooled prevalence of antimicrobial treatment among 4129 cases who did not require treatment was 45% (95% CI, 39–50). Isolation of gram-negative pathogens (odds ratio [OR], 3.58; 95% CI, 2.12–6.06), pyuria (OR, 2.83; 95% CI, 1.9–4.22), nitrite positivity (OR, 3.83; 95% CI, 2.24–6.54), and female sex (OR, 2.11; 95% CI, 1.46–3.06) increased the odds of receiving treatment. The rates of treatment were higher in studies with $\geq 100\,000$ cfu/mL cutoff values compared with $< 10\,000$ cfu/mL for bacterial growth ($P, .011$). The implementation of educational and organizational interventions designed to eliminate the overtreatment of ASB resulted in a median absolute risk reduction of 33% (range_{ARR}, 16–36%, median_{RRR}, 53%; range_{RRR}, 25–80%).

Conclusion. The mismanagement of ASB remains extremely frequent. Female sex and the overinterpretation of certain laboratory data (positive nitrites, pyuria, isolation of gram-negative bacteria and cultures with higher microbial count) are associated with overtreatment. Even simple stewardship interventions can be particularly effective, and antimicrobial stewardship programs should focus on the challenge of differentiating true urinary tract infection from ASB.

Keywords. antimicrobial; intervention; urinary tract infection; UTI.

A positive urine culture for bacteria or fungi, in the absence of symptoms (reported in the literature simply as asymptomatic bacteriuria [ASB] for reasons of convenience [1]) is a common clinical finding, especially among the inpatient population, the elderly, and patients with indwelling urinary catheters [2]. Antimicrobial therapy has no role in the majority of cases of ASB, and withholding treatment has no effect in mortality or renal function [2, 3]. Moreover, overtreatment of ASB may result in a number of undesirable outcomes, such as disturbance of the intestinal flora that increases the risk for *Clostridium difficile* infection, antibiotic resistance, and increased health

care-associated costs [4, 5]. Furthermore, treatment of ASB may eliminate low-virulence strains that suppress the development of uropathogens, thus counterintuitively promoting the development of symptomatic urinary tract infections (UTIs) [6, 7].

Responding to this challenge, the Infectious Diseases Society of America (IDSA) released evidence-based recommendations to guide health care professionals in their approach to ASB [8]. In spite of these recommendations, ASB remains one of the most common causes of antimicrobial overprescription in both acute [9] and long-term care [10]. For example, in a recent prospective study conducted among hospitalized patients, overtreatment of ASB contributed 17% of total antimicrobial overprescriptions [9]. Nonetheless, the cumulative frequency of ASB overtreatment across the spectrum of care has not been well studied. The aim of this systematic review and meta-analysis was to estimate the overall prevalence of ASB overtreatment. We also identified factors associated with increased odds of overtreatment, as well as quantified the efficacy of initiatives aimed at improving ASB management.

METHODS

This study was conducted according to the PRISMA checklist [11].

Received 22 June 2017; editorial decision 20 September 2017; accepted 22 September 2017.

^aAuthors contributed equally to this work.

Correspondence: E. Mylonakis, MD, PhD, Infectious Diseases Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital 593 Eddy Street, POB, 3rd Floor, Suite 328/330, Providence, RI 02903 (emylonakis@lifespan.org).

Open Forum Infectious Diseases®

© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

DOI: 10.1093/ofid/ofx207

Data Sources and Search

Three researchers (MF, AK, PO) searched the PubMed and EMBASE databases from 2004 up to August 24, 2016, using the term “{asymptomatic AND (bacteriuria OR UTI OR (urinary tract infection))} AND (treatment or therapy or antimicrobial or antibacterial or antibiotic).” We screened citations by abstract and title and only assessed publications in English, French, or Spanish. After the initial selection of eligible studies, their references were also reviewed. We also contacted the study authors as needed to obtain clarifications or additional information that could facilitate our analysis. Case series, case reports, and conference abstracts were not considered for inclusion in our analysis.

Study Selection

We elected to begin our search for eligible studies published in 2004, as this was the year when the IDSA guidelines on ASB management [8] were accepted for publication, a clear indication that at that time enough published evidence existed to support the withholding of treatment in ASB cases. Some of the studies included cases from prior to 2004, and this allowed us to compare the management of ASB before and after the publication of the IDSA guidelines.

To be considered for inclusion, studies had to report the total number of ASB cases that did not warrant antimicrobial treatment according to the IDSA guidelines, as well as the number of cases that were inappropriately treated. Furthermore, we required that eligible studies clarify whether the antimicrobial treatment was specifically administered for the management of ASB and not for a different indication. Studies in which patients with ASB were treated within the context of a research protocol were excluded. Studies performed in populations undergoing surgical procedures with implantation of prostheses, solid organ transplant recipients, and patients with neobladders were also excluded, as no specific recommendations on these subpopulations are offered by the IDSA guidelines [8]. In studies that reported on interventions aimed at reducing ASB overtreatment, only the baseline period before the intervention was considered.

Definitions

Asymptomatic bacteriuria was defined as the isolation of cultivatable microorganisms without the presence of symptoms and signs suggestive of UTI. For convenience, and in accordance with previous reports [1], the term “bacteriuria” was used to describe the presence of bacteria or fungi throughout the manuscript, as funguria cases are commonly included in previously published analyses and could not be studied separately as no distinct rates were provided [1, 12–14]. Instead, as detailed below, we performed a subgroup analysis without the studies that included funguria cases.

We did not employ specific cutoffs for clinically significant growth or impose restrictions on the number of organisms isolated. This broad definition was employed to ensure that inappropriate treatment of ASB was adequately captured, regardless

of whether the ASB case in question stemmed from colonization or sample contamination. Patients with bacteriuria and symptoms/signs suggestive of infection were only considered to have ASB when the signs/symptoms could be clearly attributed to a different cause. In line with the IDSA recommendations [8], antimicrobial treatment of ASB was considered appropriate for pregnant patients and patients undergoing urologic procedures with a high likelihood of bleeding. For our secondary analysis, pyuria was defined as the presence of at least 5 white blood cells (WBC)/high-powered field (HPF) whereas hematuria was defined as the presence of at least 10 red blood cells (RBC)/HPF.

Data Extraction and Quality Assessment

Our primary outcome of interest was the rate of inappropriate treatment of ASB and was calculated by dividing the number of ASB cases in which antimicrobial therapy was inappropriately prescribed by the total number of ASB cases in which no treatment was warranted, according to the IDSA guidelines [8]. As a secondary outcome, we sought to identify factors that were associated with ASB overtreatment in the included study cohorts.

Two researchers (MF, AK) extracted data independently; discrepancies between them were resolved by consensus, and data are summarized in Table 1 and Supplementary Table 2. The methodological quality of eligible studies was assessed with the Newcastle–Ottawa Quality Assessment Scale (NOS) (see Supplementary Table 1) [15]. For each study parameter that met adequate quality standards, a star was awarded to the study. Studies that were judged to be of adequate quality in all 6 of the examined study parameters were awarded a maximum of 6 stars. An NOS rating of 5 stars or higher was considered adequate for the purposes of our analysis.

Data Analysis

The meta-analysis was conducted using the random-effects model, proposed by DerSimonian and Laird, to estimate the pooled rates and 95% confidence intervals of the primary outcome [16]. The Freeman-Tukey arcsine transformation was employed to ensure the inclusion of studies that reported extreme rates (rates near 0 or 1) [17]. The tau-squared statistic was calculated to assess the heterogeneity between the studies, and possible sources of heterogeneity were further explored by meta-regression analysis (Knapp and Hartung model) [18]. Using this methodology, we performed a temporal sensitivity analysis that included only the studies performed in 2006 and after to assess the effect of the introduction of the IDSA guidelines on the reported rates. A subgroup analysis without the studies that included funguria cases was also conducted. We used Egger’s regression test (ET) as an indicator of small study effect [19]. A time-trend analysis was performed by transforming the model coefficients to rates and plotting them against the median year along with the reported prevalence rates [20].

We also performed a secondary analysis of the studies that reported on factors associated with ASB treatment. This

Table 1. Characteristics of Included Studies: Study Midyear and Country, Design, Number of ASB Cases That Were Treated Inappropriately, Number of ASB Cases That Did Not Require Treatment, Prevalence of Overtreatment, Study Setting, Cutoff Used for Screening, Age and Sex of Participants

Author (Year)	Country	Design	ASB Treated ^a	No. of ASB ^a	Rate of Inappropriate Treatment of ASB	Setting ^{b,c}	Cutoff, cfu ^c	Age, y ^{c,d}	Sex ^c
Chiu [24] (2010)	Canada	Retrospective	23	30	76.67	Tertiary care teaching hospital	None	≥18	NR
Dalen [25] (2003)	Canada	Prospective	15	29	51.72	1000-bed teaching hospital, 138-bed hospital	100 000 000; 1 000 000 for fungi	Mean, 77.8; range, 52–94	NR
Irfan [13] (2012)	Canada	Prospective	93	160	58.13	2 academic, tertiary acute care hospitals	100 000	Mean, 74.1; SD, 12.8	Female 71.3%
Leis [34] (2012)	Canada	Prospective	12	21	57.14	2 acute care teaching hospitals	NR	≥18	NR
Leis [33] (2013)	Canada	Prospective	26	57	45.61	Acute care teaching hospital	NR	≥18	NR
Silver [40] (2006)	Canada	Prospective	43	67	64.18	1100-bed university-affiliated teaching hospital	100 000	≥18	Female 55%
Winter-berger [42] (2013)	Canada	Prospective	15	31	48.39	Medicine and surgery wards, noncatheterized	NR	≥18	NR
Al Ray [44] (2005)	USA	Retrospective	25	43	58.14	ICU, 772-bed teaching hospital	100 000	≥18	NR
Chowdhury [4] (2010)	USA	Retrospective	30	64	46.88	Inpatients and nursing home residents	100 000, 100 for catheterized*	≥18	Female 68%
Cope [11] (2007)	USA	Retrospective	53	164	32.32	Tertiary care academic hospital, catheterized	10 000	Median, 67; range, 21–88	Male 96%
Drekonia [26] (2011)	USA	Prospective	8	45	17.78	Veterans Affairs Medical Center	None	≥18	NR
Gau [27] (2004)	USA	Retrospective	25	50	50.00	Community hospital	50 000	≥65; mean, 83; SD, 8	Female 84%
Grein [21] (2014)	USA	Retrospective	62	164	37.8	900-bed tertiary care academic teaching hospital, 550-bed county hospital, 389-bed community hospital	1000	>18	Female 67%
Hartley [28] (2008)	USA	Retrospective	60	94	63.83	University-affiliated hospital	NR	≥18	NR
Heintz [14] (2010)	USA	Retrospective	33	155	21.29	University-affiliated hospital VRE positive	None	>18	NR
Kelley [30] (2012)	USA	Retrospective	66	107	61.68	Academic medical center	10 000	>18	Female 78.5%
Khair [31] (2011)	USA	Prospective	46	119	38.66	1250-bed teaching hospital, Enterococci	50 000; 5000 among catheterized*	Range, 17–96	NR
Khawcha roenporn [32] (2008)	USA	Retrospective	37	184	20.11	University medical center	10 000	Median, 59; range, 40–73	Female 76%
Leuck [36] (2009)	USA	Prospective	39	95	41.05	Veterans Affairs Medical Center	100 000/None**	≥18	NR
Lin [37] (2009)	USA	Retrospective	60	183	32.79	2 tertiary care, academic teaching hospitals Enterococci	1000	NR	Male 61%
Al Mohajer [38] (2009)	USA	Retrospective	101	326	30.98	Veterans Affairs Medical Center, <i>S. aureus</i>	10 000***	Mean 66.2	Male >90%
Trautner [41] (2011)	USA	Prospective	167	488	34.22	3 medicine wards and 2 long-term care wards, Veterans Health Care System, catheterized	1000	≥18	NR

Table 1. Continued

Author (Year)	Country	Design	ASB Treated ^a	No. of ASB ^a	Rate of Inappropriate Treatment of ASB	Setting ^{b,c}	Cutoff, cfu ^e	Age, y ^{c,d}	Sex ^c
Zabarsky [43] (2003)	USA	Prospective	23	34	67.65	Veterans Affairs Medical Center, long-term care facility	100 000	Median, 70; range, 42–98	Male 100%
Lepeule [35] (2011)	France	Prospective	19	117	16.24	13 hospitals ESBL positive	NR	Median, 67; range, 1–92	Female 63%
Saurel [39] (2005)	France	Retrospective	61	108	56.48	Medicine and surgery departments, university hospital	10 000	≥18	Female 63%
Pavese [45] (2005)	France	Prospective	41	63	65.08	University-associated hospital	10 000	≥18	Female 60%
Cai [23] (2011)	Italy	Retrospective	361	699	51.65	Department of urology, tertiary care and regional hospitals	100 000	≥18	Female 100%
Hermida Perez [29] (1999)	Spain	Prospective	44	88	50	NR	100 000	≥14	Female 100%
Lee [12] (2011)	Korea	Retrospective	70	219	31.96	900-bed university-affiliated tertiary care hospital	100 000	≥18	Female 73.51%
Blakiston [22] (2011)	New Zealand	Retrospective	57	125	45.6	Over-65 rehabilitation ward of a secondary level care hospital	1000	≥65	NR

Abbreviations: ASB, asymptomatic bacteriuria; ED, emergency department; ESBL, extended-spectrum beta-lactamases; ICU, intensive care unit; NR, not reported; *S. aureus*, *Staphylococcus Aureus*; UTI, urinary tract infections; VRE, vancomycin-resistant enterococcus. *The lower count was used as a cut-off for the purposes of the respective sub-analysis. **Only the portion of the cohort that used the 100 000 cfu/mL cut-off was included in the respective sub-analysis. In all other cases, the full cohort was used. ***The majority of the cohort used this cut-off, so it was employed for the respective sub-analysis.

^aAsymptomatic bacteriuria cases (not requiring treatment).

^bED, ESBL, ICU, *S. aureus*, UTI, VRE.

^cNot reported.

^dStandard deviation.

secondary analysis only included factors that were assessed by a minimum of 3 studies [20]. Pooled relative effects were reported as unadjusted odds ratios (ORs) and 95% confidence intervals, calculated with the aid of the random-effects model. The heterogeneity among studies was further assessed with the tau-squared statistic. In studies that implemented interventions aimed at reducing ASB overtreatment, the absolute risk reduction (ARR) and relative risk reduction (RRR) that followed the intervention were calculated for each site and then summarized into median and range. To facilitate the presentation of our results, all percentages reported in the text were rounded up to the nearest integer.

Statistical analysis was conducted using the STATA v. 13 software package (STATA Corporation, College Station, TEXAS). Statistical significance was defined as a *P* value of less than .05.

RESULTS

A total of 2848 articles published from January 1, 2004, to August 24, 2016, were identified. Thirty studies were considered eligible and were incorporated into our analysis after quality evaluation. The selection process is depicted in Figure 1. The 30 studies included in our analysis reported on a total of 4129

ASB cases (Table 1) [1, 4, 12–14, 21–45]. The majority of studies were performed in North America (16 in the United States [1, 4, 14, 21, 26–28, 30–32, 36–38, 41, 43, 44] and 7 in Canada [13, 24, 25, 33, 34, 40, 42]) and Europe (3 in France [35, 39, 45], 1 in Italy [23], and 1 in Spain [29]). Finally, 1 study each was performed in New Zealand [22] and South Korea [12]. Contact with study authors of potentially relevant articles for additional data and a systematic search of article references failed to yield additional data and studies.

Remarkably, the pooled rate of inappropriate treatment was 45% (95% CI, 39–50; τ^2 , 0.08). Specifically, the rate of inappropriate treatment was 45% in North America (95% CI, 38–51; 40% in the United States, 58% in Canada) and 47% in Europe (95% CI, 32–62) (Figure 2). No small study effect across the included studies was detected (ET, 1.01; P_{ET^2} , 0.161). Twenty-two out of the 30 studies were performed in inpatient populations and had a rate of inappropriate treatment of 45% (95% CI, 38–51) [1, 12–14, 21, 22, 24–28, 31, 33–36, 39–42, 44, 45]. Two were performed in outpatient settings [23, 29], 1 in the emergency department [32], 1 among nursing home residents [43], and 4 in a mixture of settings [4, 30, 37, 38]. Five of the studies reported rates of




Figure 1. PRISMA flow diagram. Abbreviation: ASB, asymptomatic bacteriuria.




Figure 2. Forest plot of included studies. Rates of overtreatment of asymptomatic bacteriuria stratified by region. ES, effect size.

inappropriate treatment among patients with indwelling urinary catheters, and their pooled prevalence was similar to the overall rate (44%; 95% CI, 34–55) [1, 24, 25, 36, 41].

In a sensitivity analysis, we pooled the rates from studies that were performed in 2006 or later to estimate the effect of the introduction of the IDSA guidelines on inappropriate treatment

rates. For the 23 studies that were performed in the years 2006–2014 [1, 4, 12–14, 21–24, 26, 28, 30–38, 40, 41], the pooled rate was 41% (95% CI, 35–47; τ^2 , 0.08), whereas for the 7 studies performed from 1996 to 2005 [25, 27, 29, 39, 43–45], it was 56% (95% CI, 52–61; $\tau^2 < 0.001$). This difference was statistically significant (coeff, 0.31; P , .028), however, we noted no significant

time trend in the subanalysis for the years 2006–2014 (P , .885), indicating that the potential beneficial effect from the publication of structured guidelines might have reached a plateau.

As discussed in the “Methods,” we explored the impact of factors potentially associated with inappropriate ASB treatment. Our analysis demonstrated that patients with gram-negative isolates had a higher chance of receiving inappropriate treatment (OR, 3.58; 95% CI, 2.12–6.06; τ^2 , 0.08; ET, 9.48; P_{EP} , 0.131), based on 3 studies with 547 patients [1, 12, 21]. This was also the case for female patients (OR, 2.11; 95% CI, 1.46–3.06; τ^2 < 0.001; ET, 0.9; P_{EP} , 0.608), based on 5 studies with 891 participants [1, 12, 13, 21, 32]. Patients with pyuria were also more likely to be treated inappropriately, based on 5 studies involving 865 participants (OR, 2.83; 95% CI, 1.9–4.22; τ^2 , 0.06; ET, 5.26; P_{EP} , 0.252) [12, 13, 31, 32, 37].

Regarding the impact of cutoffs used for detecting bacteriuria in the rate of inappropriate treatment, among the 30 included studies, 9 used a cutoff of $\geq 100\,000$ cfu/mL or higher, and these studies had a pooled prevalence of inappropriate treatment of 53% (95% CI, 46–61) [12, 13, 23, 25, 29, 36, 40, 43, 44]. Studies that used lower cutoffs (and thus lower bacterial counts) reported lower prevalence of inappropriate ASB treatment. Specifically, 7 studies that used cutoffs between 10 000 and 100 000 cfu/mL had a pooled prevalence of 44% (95% CI, 32–57) [1, 27, 30, 32, 38, 39, 45], while 6 studies that used a cutoff of <10 000 cfu/mL had a pooled prevalence of 38% (95% CI, 34–42) [4, 21, 22, 31, 37, 41]. Notably, the rate was significantly lower among studies that utilized lower cutoff values to define bacteriuria (coeff, -0.15 ; P , .035). A significant difference was noted while comparing the rates reported between studies using cut-offs <10 000 cfu/mL vs those using $\geq 100\,000$ cfu/mL (coeff, -0.29 ; P , .011). A sensitivity analysis that recalculated the rate excluding studies with funguria cases [1, 12–14, 25, 36] did not result in any difference (45%; 95% CI, 39–51; τ^2 , 0.09).

Based on 4 studies with 727 patients, positivity for nitrites in urinalysis also increased the risk of inappropriate administration of antimicrobial therapy (OR, 3.83; 95% CI, 2.24–6.54; τ^2 , 0.16; ET, -1.93 ; P_{EP} , 0.861) [12, 13, 21, 32]. Interestingly, the risk of inappropriate ASB treatment appeared similar among patients in surgical and nonsurgical units (OR, 1.04; 95% CI, 0.67–1.55) [12, 13, 21, 40], as well as among patients admitted to intensive care units (ICUs) and those in general hospital wards (OR, 0.67; 95% CI, 0.33–1.35) [12, 13, 21, 40]. Furthermore, no difference in the risk of inappropriate treatment was reported among diabetic vs nondiabetic patients (OR, 0.69; 95% CI, 0.39–1.22) [12, 13, 32], patients with indwelling urinary catheters vs noncatheterized patients (OR, 0.95; 95% CI, 0.58–1.54) [12, 13, 21, 22, 33, 44] or patients with hematuria vs those without hematuria (OR, 1.98; 95% CI, 0.76–5.16) [12, 13, 37].

Finally, among the 30 included studies, 8 reported on interventions to reduce the rate of inappropriate treatment of ASB from 2002 to 2013 (Supplementary Table 2). Five of these

studies were performed in inpatient settings [13, 33, 41, 42, 45], 1 was performed in a nursing home [43], and 2 involved different settings [4, 30]. The duration of the baseline period varied from 1 to 12 months (treatment rates, 38–74%), whereas the intervention period varied from 2 to 30 months. Importantly, substantial improvements in the rate of inappropriate ASB treatment were reported after the implementation of these relatively simple measures (median_{ARR}, 33%; range_{ARR}, 16–36%; median_{RRR}, 53%; range_{RRR}, 25–80%). One study reported data on a 1-year maintenance period after the completion of the intervention; a sustained reduction was observed (29% maintenance vs 38% baseline treatment rate).

DISCUSSION

In the “Choosing Wisely Campaign,” the American Geriatrics Society and the American Board of Internal Medicine Foundation listed the unnecessary use of antimicrobials for ASB as one of the top 5 overused services [46]. We found that almost half of the ASB cases were managed inappropriately, a finding that justifies this level of concern, and the rate remained alarmingly high (40%), even after the introduction of the IDSA evidence-based recommendations. Women and patients with gram-negative bacteriuria had 2 and 4 times greater odds of being treated inappropriately, respectively. Also, overinterpretation of urinalysis that places undue emphasis on the presence of pyuria, nitrite positivity, and higher bacterial counts appears to drive inappropriate antimicrobial prescription for ASB. Interestingly, the challenge of reducing ASB overtreatment may be surmountable, as relatively simple educational and/or organizational interventions appear to reduce the incidence of inappropriate prescribing practices.

Challenges in the clinical differentiation between ASB and UTI may offer a partial explanation for the excessive overtreatment of ASB [47]. Of note, the presence of nonspecific signs and symptoms or comorbid conditions in such patients can be misleading [26, 47]. No association between these nonurinary indications and the presence or absence of bacteriuria has been suggested, and there is no evidence to justify treating bacteriuria in this context [48]. Another key aspect in understanding overtreatment is the undue reliance on the results of laboratory studies. For example, in a survey of physicians at a Swiss hospital, decision-making based on laboratory findings alone was the most commonly reported reason for overprescribing (reported by 17 out of 21 participants) [49]. This suggests that practitioners may decide to commence empiric treatment for UTIs based solely on the results of laboratory tests, without considering clinical data. Conversely, this overreliance on laboratory information may also explain why no association was found between the patient’s underlying condition as represented by the site of hospitalization (surgical floor, ICU) or the presence of diabetes and the rate of ASB overtreatment. It is possible that certain “danger” results in urinalysis (bacterial counts $\geq 100\,000$,

positive nitrites, pyuria, and the presence of gram-negative bacteria) are interpreted as strengthening the likelihood of a UTI diagnosis, while the patient's history and clinical signs/symptoms may be given less consideration. However, as noted above, none of these laboratory findings has been shown to be specific for symptomatic UTI, and evidence-based recommendations discourage the use of antimicrobial agents for asymptomatic ASB in most cases, regardless of laboratory results [8].

Interestingly, among the 30 included studies, 8 implemented interventions aimed at reducing the rate of inappropriate treatment. Most of these initiatives were apparently successful and resulted in up to an 80% reduction in the inappropriate management of ASB. Our findings support that such successful interventions should aim at educating providers regarding the existing clinical guidelines [50], the natural history of ASB, and the diagnostic/therapeutic pitfalls associated with differentiating ASB cases from UTI [12]. Nonetheless, educational efforts are only part of the answer. For example, in a recent survey from a tertiary care hospital, almost 50% of the participants demonstrated a willingness to treat ASB despite knowing that this was not indicated by the IDSA guidelines [12]. Fortunately, relatively simple measures, such as didactic sessions and audit and feedback, are not only effective at reducing overtreatment, which is highlighted by the 25–80% reduction noted among the included studies, but also sustainable [41]. In 2 studies [33, 42], the introduction of the requirement that the physician should contact the microbiology lab by phone in order to acquire the results of urine cultures yielded a 37% and 75% reduction in prescribing, which underlines the role of strategies to promote appropriate ordering of urinary cultures. Specifically, it has been demonstrated that a considerable percentage of urine cultures ordered in everyday practice are not clinically indicated [34]. Importantly, unnecessary ordering of urine cultures not only contributes to inefficient utilization of laboratory resources and excess health care costs, but is also thought to drive inappropriate treatment of ASB [33, 34, 41, 51]. In fact, as demonstrated in a recent major study by Trautner et al. [41], initiatives aiming to restrict the inappropriate ordering of urine cultures significantly reduced the frequency of ASB overtreatment. As such, “urine culture stewardship” clearly has an important role to play in efforts to reduce inappropriate antibiotic prescription in the setting of ASB.

Regarding limitations of our analysis, most of the included studies were performed in inpatient populations in North America and Europe, and thus may not be applicable to other patient populations. Moreover, we were not able to estimate the effect of age on the treatment rates due to lack of uniformity in the reporting of relevant information. In addition, we were unable to perform a separate analysis of patients with spinal cord injury due to the paucity of relevant data. Future studies should investigate this question as it has been suggested that the IDSA guidelines [8] may not be widely implemented

among patients with spinal cord injury [52] due to limited relevant evidence and the inherent diagnostic challenges presented by this patient group [52]. Furthermore, given the small number of studies reporting on factors associated with overtreatment, we were unable to perform a multivariate analysis to assess for possible confounders. It should also be noted that the reported lack of an association between the site of patient hospitalization (surgical floor, ICU) or the presence of diabetes and the rate of ASB overtreatment was based on a limited patient sample and may merely stem from reduced statistical power. Future studies are needed to confirm these findings. Regarding the estimation of the effect of interventions, we performed a descriptive analysis instead of pooling the effects due to the disparity between strategies applied by different institutions.

In conclusion, the present study highlights the considerable gap between evidence-based guidelines and contemporary clinical practice in the management of ASB. Undue emphasis on laboratory results, rather than on the patient's clinical condition, appears to underlie most cases of ASB overtreatment. Evidence suggests that the challenges of differentiating symptomatic from asymptomatic bacteriuria and improving adherence to evidence-based guidelines can be overcome through a combination of educational and organizational interventions and that ASB should be a priority for antimicrobial stewardship programs.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online (ofid.oxfordjournals.org). Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgements

Author contributions. Guarantor of the article: Drs. Flokas and Mylonakis accept full responsibility for the conduct of the study, have access to the data, and have control of the decision to publish. Myrto Eleni Flokas: Dr. Flokas conceptualized and designed the study, participated in data collection, extraction, and interpretation, performed the statistical analysis, prepared tables and figures, wrote and drafted the initial manuscript, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Nikolaos Andreatos: Dr. Andreatos conceptualized and designed the study, participated in data interpretation, drafted the initial manuscript, revised the manuscript according to the reviewers' comments, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Michail Alevizakos: Dr. Alevizakos conceptualized and designed the study, participated in data interpretation, drafted the initial manuscript, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Alireza Kalbasi: Dr. Kalbasi participated in data collection, extraction, drafted the initial manuscript, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately

investigated and resolved. Pelin Onur: Dr. Onur participated in data collection, drafted the initial manuscript, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Eleftherios Mylonakis: Dr. Mylonakis conceptualized and designed the study, participated in data interpretation, reviewed and revised the manuscript, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Potential conflicts of interest. All authors: no reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Cope M, Cevallos ME, Cadle RM, et al. Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care hospital. *Clin Infect Dis* **2009**; 48:1182–8.
2. Trautner BW, Grigoryan L. Approach to a positive urine culture in a patient without urinary symptoms. *Infect Dis Clin North Am* **2014**; 28:15–31.
3. Raz R. Asymptomatic bacteriuria. Clinical significance and management. *Int J Antimicrob Agents* **2003**; 22(Suppl 2):45–7.
4. Chowdhury F, Sarkar K, Branche A, et al. Preventing the inappropriate treatment of asymptomatic bacteriuria at a community teaching hospital. *J Community Hosp Intern Med Perspect* **2012**; 2: doi: 10.3402/jchimp.v2i2.17814.
5. Courjon J, Pulcini C, Cua E, et al. Antibiotics-related adverse events in the infectious diseases department of a French teaching hospital: a prospective study. *Eur J Clin Microbiol Infect Dis* **2013**; 32:1611–6.
6. Wullt B, Svanborg C. Deliberate establishment of asymptomatic bacteriuria—a novel strategy to prevent recurrent UTI. *Pathogens* **2016**; 5: doi: 10.3390/pathogens5030052.
7. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? *Clin Infect Dis* **2012**; 55:771–7.
8. Nicolle LE, Bradley S, Colgan R, et al; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* **2005**; 40:643–54.
9. Hecker MT, Aron DC, Patel NP, et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. *Arch Intern Med* **2003**; 163:972–8.
10. Phillips CD, Adepoju O, Stone N, et al. Asymptomatic bacteriuria, antibiotic use, and suspected urinary tract infections in four nursing homes. *BMC Geriatr* **2012**; 12:73.
11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* **2009**; 6:e1000097.
12. Lee MJ, Kim M, Kim NH, et al. Why is asymptomatic bacteriuria overtreated?: A tertiary care institutional survey of resident physicians. *BMC Infect Dis* **2015**; 15:289.
13. Irfan N, Brooks A, Mithoowani S, et al. A controlled quasi-experimental study of an educational intervention to reduce the unnecessary use of antimicrobials for asymptomatic bacteriuria. *PLoS One* **2015**; 10:e0132071.
14. Heintz BH, Cho S, Fujioka A, et al. Evaluation of the treatment of vancomycin-resistant enterococcal urinary tract infections in a large academic medical center. *Ann Pharmacother* **2013**; 47:159–69.
15. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 December 2016.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* **1986**; 7:177–88.
17. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. *Arch Public Health* **2014**; 72:39.
18. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. *BMC Med Res Methodol* **2008**; 8:79.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* **1997**; 315:629–34.
20. Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. *J Infect* **2016**; 73:547–57.
21. Grein JD, Kahn KL, Eells SJ, et al. Treatment for positive urine cultures in hospitalized adults: a survey of prevalence and risk factors in 3 medical centers. *Infect Control Hosp Epidemiol* **2016**; 37:319–26.
22. Blakiston M, Zaman S. Nosocomial bacteriuria in elderly inpatients may be leading to considerable antibiotic overuse: an audit of current management practice in a secondary level care hospital in New Zealand. *Infect Drug Resist* **2014**; 7:301–8.
23. Cai T, Mazzoli S, Migno S, et al. Development and validation of a nomogram predicting recurrence risk in women with symptomatic urinary tract infection. *Int J Urol* **2014**; 21:929–34.
24. Chiu J, Thompson GW, Austin TW, et al. Antibiotic prescribing practices for catheter urine culture results. *Can J Hosp Pharm* **2013**; 66:13–20.
25. Dalen DM, Zvonar RK, Jessamine PG. An evaluation of the management of asymptomatic catheter-associated bacteriuria and candiduria at The Ottawa Hospital. *Can J Infect Dis Med Microbiol* **2005**; 16:166–70.
26. Drekonja DM, Gnad C, Kuskowski MA, Johnson JR. Urine cultures among hospitalized veterans: casting too broad a net? *Infect Control Hosp Epidemiol* **2014**; 35:574–6.
27. Gau JT, Shibeshi MR, Lu IJ, et al. Interexpert agreement on diagnosis of bacteriuria and urinary tract infection in hospitalized older adults. *J Am Osteopath Assoc* **2009**; 109:220–6.
28. Hartley S, Valley S, Kuhn L, et al. Overtreatment of asymptomatic bacteriuria: identifying targets for improvement. *Infect Control Hosp Epidemiol* **2015**; 36:470–3.
29. Hermida Pérez JA, Loro Ferrer JE. Asymptomatic bacteriuria in women. Epidemiological, pathologic and therapeutic study. *Arch Esp Urol* **2004**; 57:784–804.
30. Kelley D, Aaronson P, Poon E, et al. Evaluation of an antimicrobial stewardship approach to minimize overuse of antibiotics in patients with asymptomatic bacteriuria. *Infect Control Hosp Epidemiol* **2014**; 35:193–5.
31. Khair HN, VanTassel P, Henderson JP, et al; CDC Prevention Epicenters Program. Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria. *J Hosp Infect* **2013**; 85:183–8.
32. Khawcharoenporn T, Vasoo S, Ward E, Singh K. Abnormal urinalysis finding triggered antibiotic prescription for asymptomatic bacteriuria in the ED. *Am J Emerg Med* **2011**; 29:828–30.
33. Leis JA, Rebick GW, Daneman N, et al. Reducing antimicrobial therapy for asymptomatic bacteriuria among noncatheterized inpatients: a proof-of-concept study. *Clin Infect Dis* **2014**; 58:980–3.
34. Leis JA, Gold WL, Daneman N, et al. Downstream impact of urine cultures ordered without indication at two acute care teaching hospitals. *Infect Control Hosp Epidemiol* **2013**; 34:1113–4.
35. Lepeule R, Leflon-Guibout V, Vanjak D, et al; Groupe des Référents en Infectiologie d'Ile-de-France (GRIF). Clinical spectrum of urine cultures positive for ESBL-producing *Escherichia coli* in hospitalized patients and impact on antibiotic use. *Med Mal Infect* **2014**; 44:530–4.
36. Leuck AM, Wright D, Ellingson L, et al. Complications of Foley catheters—is infection the greatest risk? *J Urol* **2012**; 187:1662–6.
37. Lin E, Bhusal Y, Horwitz D, et al. Overtreatment of enterococcal bacteriuria. *Arch Intern Med* **2012**; 172:33–8.
38. Al Mohajer M, Musher DM, Minard CG, Darouiche RO. Clinical significance of *Staphylococcus aureus* bacteriuria at a tertiary care hospital. *Scand J Infect Dis* **2013**; 45:688–95.
39. Saurel N, Pavese P, Boyer L, et al. Adequacy of antibiotic therapy to guidelines for urinary tract infection in hospital. *Med Mal Infect* **2006**; 36:369–74.
40. Silver SA, Baillie L, Simor AE. Positive urine cultures: a major cause of inappropriate antimicrobial use in hospitals? *Can J Infect Dis Med Microbiol* **2009**; 20:107–11.
41. Trautner BW, Grigoryan L, Petersen NJ, et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. *JAMA Intern Med* **2015**; 175:1120–7.
42. Wintemberger C. Not providing results of UT colonization. *Med Mal Infect* **2014**; 44:447–8.
43. Zabarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. *Am J Infect Control* **2008**; 36:476–80.
44. Al Raiy B, Jahamy H, Fakhri MG, Khatib R. Clinicians' approach to positive urine culture in the intensive care units. *Infect Dis Clin Pract* **2007**; 15:382–4.
45. Pavese P, Saurel N, Labarère J, et al. Does an educational session with an infectious diseases physician reduce the use of inappropriate antibiotic therapy for inpatients with positive urine culture results? A controlled before-and-after study. *Infect Control Hosp Epidemiol* **2009**; 30:596–9.
46. Choosing Wisely. An initiative of the ABIM foundation. Available at: <http://www.choosingwisely.org/societies/american-geriatrics-society/>. Accessed 5 May 2017.
47. Walker S, McGeer A, Simor AE, et al. Why are antibiotics prescribed for asymptomatic bacteriuria in institutionalized elderly people? A qualitative study of physicians' and nurses' perceptions. *CMAJ* **2000**; 163:273–7.
48. Boscia JA, Kobasa WD, Abrutyn E, et al. Lack of association between bacteriuria and symptoms in the elderly. *Am J Med* **1986**; 81:979–82.

49. Eyer M, Läng M, Aujesky D, Marschall J. Overtreatment of asymptomatic bacteriuria: a qualitative study. *Open Forum Infect Dis* **2015**; 2:164.
50. Drekonja DM, Abbo LM, Kuskowski MA, et al. A survey of resident physicians' knowledge regarding urine testing and subsequent antimicrobial treatment. *Am J Infect Control* **2013**; 41:892–6.
51. Naik AD, Trautner BW. Doing the right thing for asymptomatic bacteriuria: knowing less leads to doing less. *Clin Infect Dis* **2014**; 58:984–5.
52. Pannek J. Treatment of urinary tract infection in persons with spinal cord injury: guidelines, evidence, and clinical practice. A questionnaire-based survey and review of the literature. *J Spinal Cord Med* **2011**; 34:11–5.